OyebimpeOluyemisiAdesinaMD

Hematology • Seattle, WA

Sickle Cell & Other Anemias

Assistant Professor, University of Washington, Seattle, WA

Join to view full profile

Dr. Adesina is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Adesina's full profile

Already have an account?

Office
825 Eastlake Ave E
MS# CE3-300
Seattle, WA 98109
Phone+1 206-606-1621

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2012 - 2015
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2009 - 2011
University of California San Francisco School of MedicineClass of 2008

Certifications & Licensure

CA State Medical License 2009 - 2025
WA State Medical License 2016 - 2021
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

Publications & Presentations

PubMed

Rates of strokes in Californians with sickle cell disease in the post-STOP era.
Olubusola Oluwole, Ann M Brunson, Oyebimpe O Adesina, Shaina M Willen, Theresa H M Keegan
Blood. 2024-12-12
Should we use bisphosphonates to treat bone complications in sickle cell disease?
Jahnavi Gollamudi, Oyebimpe Adesina
Hematology. American Society of Hematology. Education Program. 2024-12-06
Alendronate preserves bone mineral density in adults with sickle cell disease and osteoporosis.
Oyebimpe O Adesina, Isaac C Jenkins, Fábio Galvão, Ana C de Moura, Kleber Y Fertrin
Osteoporosis International. 2024-10-22

Press Mentions

A Game-Changing Cure for Sickle Cell May Be ComingNovember 2nd, 2023